EBMT/EHA CAR T Cell Meeting. February 15-17, 2024. Durable complete response achieved in a relapsed/refractory diffuse large B cell lymphoma (DLBCL) patient treated with a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout: Case report from the CB-010 ANTLER trial...
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietie stem cell transplantation in B cell malignancies [ J ]. J Hematol Oneol, 2017, 10 ( 1 ) : 35. DOI: 10.1186/s13045-017 -0405 -3.Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation...
The genetically engineered allogeneic CD19-targeted CAR-T cells (code name: TyU19) were produced according to the workflow illustrated in Figure 1A. Each batch started with 1 × 109 peripheral blood mononuclear cells (PBMCs), which was approximately 1/10 of a single donation from a healthy do...
Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital): 一种CD19抑制剂药物,由Tianjin First Center Hospital (天津市第一中心医院)公司最早进行研发,目前全球最高研发状态为临床1期,作用机制: CD19抑制剂(B淋巴细胞抗原CD19抑制剂),治疗领域: 免疫系统疾病,血
Here, we describe an optimized construct for site-specific integration (SSI)-based co-expression of the anti-rejection CD70 CAR and a CD19 CAR from a single locus. The resulting CAR T cell product showed high homogeneity, enrichment of CD70 CAR/CD19 CAR double positive cells, efficacy ...
T cells expressing chimeric antigen receptors (CARs) targeting CD19 (CD19-CARTs) have shown remarkable activity in B-cell acute lymphoblastic leukemia (B-ALL), with reported complete remission (CR) rates ranging from 61 to 93%, even in patients with multiply relapsed disease.1, 2, 3, 4, ...
The antitumor activity of CRISPR/Cas9-edited allogeneic anti-CD19 CAR-T (CAR-T19) cells was assessed in vitro, in animal models, and in patients with relapsed/refractory (R/R) acute B cell lymphoblastic leukemia (B-ALL) or diffuse large B cell lymphoma. ...
S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017). This article reports the results from a phase II study that showed an objective response rate of 82% with the CD19 CAR-T cell therapy axicabta...
In addition, a mouse study to investigate the effect of donor-derived CD19 CAR-T cells in allogeneic HSCT showed that allogeneic CAR-T cells exert potent graft-versus-lymphoma activity and decreased GvHD and identified that TNFRSF9 co-stimulated CAR-T cells increased the occurrence of GvHD [...
The efficacy and safety of donor-derived anti-CD19 CAR T cells vs DLI for the management of relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allo-hematopoietic stem cell transplantation (HSCT) remain unclear. Thirteen B-ALL patients with relapsed after allo-HSCT and thus were treated...